In brief, factors such as failure to achieve SVR, cirrhosis, reduced albumin levels, elevated alpha-fetoprotein (AFP), low platelet count, and the presence of indeterminate liver nodules before starting DAA therapy are associated with an increased risk of HCC. Here, AFP is linked to Cirrhosis.